Together we will beat cancer

Donate now

Drug decision

Showing 10 out of 10 results
A magnified image of squamous cell carcinoma, the most common type of cervical cancer

The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland. The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland.

by Tim Gunn | News | 16 May 2023

16 May 2023

Breast cancer cells

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England.  Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

by Tim Gunn | News | 11 April 2023

11 April 2023

Breast cancer cell seen through a scanning electron microscope

The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales. The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales.

by Tim Gunn | News | 14 November 2022

14 November 2022

A prostate cancer cell.

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

by Jacob Smith | News | 13 September 2022

13 September 2022

Lymphoma cells

Ibrutinib, a drug used to treat Waldenstrom’s macroglobulinaemia, is not being recommended by the National Institute for Health and Care Excellence in England Ibrutinib, a drug used to treat Waldenstrom’s macroglobulinaemia, is not being recommended by the National Institute for Health and Care Excellence in England

by In collaboration with PA Media Group | News | 23 May 2022

23 May 2022